Phase II study of skin toxicity dosing of IRESSA (gefitinib) as monotherapy in recurrent and/or metastatic squamous cell carcinoma of the head and neck

Trial Profile

Phase II study of skin toxicity dosing of IRESSA (gefitinib) as monotherapy in recurrent and/or metastatic squamous cell carcinoma of the head and neck

Suspended
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2006

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Dec 2006 Status change
    • 07 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top